Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.

ABSTRACT:

Background

The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.

Methods

We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24 hours after starting organ support in the intensive care unit (ICU), were randomly assigned to receive tocilizumab (8 mg per kilogram of body weight), sarilumab (400 mg), or standard care (control). The primary outcome was respiratory and cardiovascular organ support-free days, on an ordinal scale combining in-hospital death (assigned a value of -1) and days free of organ support to day 21. The trial uses a Bayesian statistical model with predefined criteria for superiority, effica

SUBMITTER: REMAP-CAP Investigators 

PROVIDER: S-EPMC7953461 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature